Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Xiaobi Huang"'
Autor:
Jiancong Wu, Xiaobi Huang, Xiaofang Li, Honglian Zhou, Xiaorao Chen, Yongyang Chen, Yudong Guo, Jian Huang, Hanqing Huang, Zhong Huang, Guoan Chen, Zhixiong Yang, Jian Zhang, Wenmei Su
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Long non-coding RNAs play critical roles in the development of lung cancer by functioning as tumor suppressors or oncogenes. Changes in the expression of LINC01279 have been associated with cell differentiation and human diseases. However, t
Externí odkaz:
https://doaj.org/article/be21cb37839347e5944177df7c4fdac2
Autor:
Yongyang Chen, Xiaoling Han, Xiaobi Huang, Honglian Zhou, Hui Yu, Lihui Wang, Zijian Liu, Baiyang Liu, Jian Huang, Yinghuan Xiong, Yang Shao, Dongqin Zhu, Zhu Liang, Zhixiong Yang, Wenmei Su
Publikováno v:
Thoracic Cancer, Vol 14, Iss 16, Pp 1430-1439 (2023)
Abstract Objectives Aberrantly expressed circular RNAs (circRNAs) have been detected in many types of tumors. Hence, they are currently investigated as candidate biomarkers for diagnostic and potential targets for therapy in cancers. The objective of
Externí odkaz:
https://doaj.org/article/8bd185bc26bc4c51a3008839f7c649ac
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
Autor:
Alasdair J. Coles, Douglas L. Arnold, Ann D. Bass, Aaron L. Boster, D. Alastair S. Compston, Óscar Fernández, Eva Kubala Havrdová, Kunio Nakamura, Anthony Traboulsee, Tjalf Ziemssen, Alan Jacobs, David H. Margolin, Xiaobi Huang, Nadia Daizadeh, Madalina C. Chirieac, Krzysztof W. Selmaj
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Background: In the 2-year CARE-MS I and II trials, alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 consecutive days 12 months later significantly improved outcomes versus subcutaneous interferon beta-1a (SC IFNB-1
Externí odkaz:
https://doaj.org/article/0fa2ae77784345bda11b4afff0c00fe1
Autor:
Yongyang Chen, Xiaoling Han, Xiaobi Huang, Honglian Zhou, Hui Yu, Lihui Wang, Zijian Liu, Baiyang Liu, Jian Huang, Yinghuan Xiong, Yang Shao, Dongqin Zhu, Zhu Liang, Zhixiong Yang, Wenmei Su
Publikováno v:
Thoracic Cancer.
Autor:
Victoria P, Werth, Richard A, Furie, Juanita, Romero-Diaz, Sandra, Navarra, Kenneth, Kalunian, Ronald F, van Vollenhoven, Filippa, Nyberg, Benjamin H, Kaffenberger, Saira Z, Sheikh, Goran, Radunovic, Xiaobi, Huang, George, Clark, Hua, Carroll, Himanshu, Naik, Francois, Gaudreault, Adam, Meyers, Catherine, Barbey, Cristina, Musselli, Nathalie, Franchimont, Victoria, Werth
Publikováno v:
New England journal of medicine, 387(4), 321-3313. Massachussetts Medical Society
New England Journal of Medicine, 387(4), 321-3313. Massachussetts Medical Society
the LILAC Trial Investigators 2022, ' Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus ', New England Journal of Medicine, vol. 387, no. 4, pp. 321-3313 . https://doi.org/10.1056/NEJMoa2118024
New England Journal of Medicine, 387(4), 321-3313. Massachussetts Medical Society
the LILAC Trial Investigators 2022, ' Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus ', New England Journal of Medicine, vol. 387, no. 4, pp. 321-3313 . https://doi.org/10.1056/NEJMoa2118024
Blood dendritic cell antigen 2 (BDCA2) is a receptor that is exclusively expressed on plasmacytoid dendritic cells, which are implicated in the pathogenesis of lupus erythematosus. Whether treatment with litifilimab, a humanized monoclonal antibody a
Autor:
Richard A, Furie, Ronald F, van Vollenhoven, Kenneth, Kalunian, Sandra, Navarra, Juanita, Romero-Diaz, Victoria P, Werth, Xiaobi, Huang, George, Clark, Hua, Carroll, Adam, Meyers, Cristina, Musselli, Catherine, Barbey, Nathalie, Franchimont, Victoria, Werth
Publikováno v:
LILAC Trial Investigators 2022, ' Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus ', The New England journal of medicine, vol. 387, no. 10, pp. 894-904 . https://doi.org/10.1056/NEJMoa2118025
The New England journal of medicine, 387(10), 894-904. Massachussetts Medical Society
The New England journal of medicine, 387(10), 894-904. Massachussetts Medical Society
Antibody-binding of blood dendritic cell antigen 2 (BDCA2), which is expressed exclusively on plasmacytoid dendritic cells, suppresses the production of type I interferon that is involved in the pathogenesis of systemic lupus erythematosus (SLE). The
Autor:
NAME:Honglian Zhou, Zijian Liu, Xiaobi Huang, Hui Yu, Zhong Huang, Yongyang Chen, Hongyi Liu, Xiaohong Xu, Zhixiong Yang, Wenmei Su
Objective Long non-coding RNAs (lncRNAs) are involved in tumorigenesis. The telomerase RNA component (TERC) is an lncRNA that functions as an essential template for the addition of the telomere repeat.The aims of our study were to determine the biolo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb097336862b2c53369718e6069d3774
https://doi.org/10.21203/rs.3.rs-1589894/v1
https://doi.org/10.21203/rs.3.rs-1589894/v1
Autor:
wenmei su, Jiancong Wu, Xiaobi Huang, Xiaofang Li, Honglian Zhou, Xiaorao Chen, Yongyang Chen, Jian Huang, Hanqing Huang, Zhong Huang, Guoan Chen, Jian Zhang, Zhixiong Yang
Long non-coding RNAs play critical roles in the development of lung cancer by functioning as tumor suppressors or oncogenes. Changes in the expression of LINC01279 have been associated with cell differentiation and human diseases. However, the mechan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5dff21d88ac16dd4095c7aa965443289
https://doi.org/10.21203/rs.3.rs-1328827/v1
https://doi.org/10.21203/rs.3.rs-1328827/v1
Autor:
Zhixiong Yang, Jiancong Wu, Zhong Huang, Honglian Zhou, Xiaorao Chen, Xiaobi Huang, Yahai Liang, Zhennan Lai, Shujun Li, Yanming Lin, Xiaoling Han, Wenmei Su
Publikováno v:
Cancer Management and Research. 12:8445-8450
Objective Cancer is closely related to age, and the incidence of cancer increases with age. However, there are few studies on the relationship between age and clinical characteristics of lung cancer. Patients and methods We collected all the consecut